Related Experiment Video
Updated: Sep 15, 2026

Cholesterol Efflux Assay
Published on: March 6, 2012
Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment
D Autran1, N Attia, M Dedecjus
1Laboratoire de Métabolisme des Lipides, Université Lyon 1, H pital de l'Antiquaille, France.
Abstract:
Deterioration of reverse cholesterol transport (RCT), an important anti-atherogenic process, may contribute to the largely unexplained severity of cardiovascular risk in type 2 diabetic patients. Among other relevant metabolic perturbations is the impairment in type 2 patients of the postprandial increase in RCT which, in normal subjects, is associated with the transfer to HDL of PL from lipolyzed chylomicrons. We have explored the possibility that improvement of postprandial lipolysis by bezafibrate might also restore the stimulated level of postprandial RCT. Twelve male patients (HbA1c 7.6 +/- 1.6% triglycerides (TG) 4.5 +/- 2.4 mmol/l) were treated for 4 weeks with 400 mg bezafibrate and compared with seven age-matched controls. Lipoproteins were analyzed over 8 h after a 1000 Kcal fat load (80% lipid), serum mediated cholesterol efflux was evaluated using 3H-cholesterol labelled Fu5AH cells. Fasting efflux was lower in patients (17.9 +/- 3.3 vs 19.9 +/- 3.0 a. units, P < 0.05) and decreased postprandially in most instead of increasing, so that area under the time-curve (AUC) was 23% lower than in controls (140 +/- 23 vs 170 +/- 25 units x h, P < 0.001) The patients' HDL failed to acquire PL and gained TG in proportion to lipemia (r = 0.660, P < 0.001). Bezafibrate restored fasting efflux (19.6 +/- 3.6 units, P < 0.005 vs pretreatment) but not postprandial increase of efflux or HDL-PL. AUC of efflux was however improved to 155 +/- 23 units h (P < 0.02). Postprandial efflux related mainly to HDL-PL in controls and patients before treatment. HDL-TG emerged as a significant negative correlate common to all groups (r = -0.674, P < 0.001 8 h after the meal). Impairment of reverse cholesterol transport in diabetic patients might therefore be due to combined postprandial deficit of PL transfer and excess accumulation of TG in HDL. The significant improvement due to fibrate treatment might thus be related to the reduction of HDL-TG contents associated with the improvement of postprandial hyperlipemia.
Insights
Bezafibrate improved reverse cholesterol transport (RCT) in type 2 diabetic patients by restoring fasting cholesterol efflux and reducing HDL triglycerides. This suggests bezafibrate may mitigate cardiovascular risk associated with impaired RCT in diabetes.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Metabolic Research
Background:
- Reverse cholesterol transport (RCT) is a key anti-atherogenic process.
- Impaired RCT and postprandial lipemia contribute to cardiovascular risk in type 2 diabetes.
- Bezafibrate's effect on postprandial RCT in diabetic patients is not well understood.
Purpose of the Study:
- To investigate if bezafibrate improves postprandial RCT in type 2 diabetic patients.
- To explore the relationship between postprandial lipolysis, HDL composition, and RCT.
- To assess bezafibrate's impact on fasting and postprandial cholesterol efflux and HDL metabolism.
Main Methods:
- Twelve male type 2 diabetic patients and seven controls were studied.
- Lipoproteins were analyzed 8 hours after a high-fat meal.
- Serum-mediated cholesterol efflux was measured using 3H-cholesterol labeled Fu5AH cells.
- Patients received 400 mg bezafibrate for 4 weeks.
Main Results:
- Diabetic patients showed lower fasting cholesterol efflux and a postprandial decrease instead of an increase.
- HDL in patients failed to acquire phospholipids and gained triglycerides postprandially.
- Bezafibrate treatment improved fasting efflux and overall postprandial efflux (AUC).
- HDL triglyceride levels negatively correlated with postprandial efflux.
Conclusions:
- Impaired RCT in type 2 diabetes may stem from reduced postprandial phospholipid transfer and increased HDL triglyceride accumulation.
- Bezafibrate treatment shows potential in improving RCT in diabetic patients, possibly by reducing HDL triglycerides and improving postprandial hyperlipemia.
Related Concept Videos
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Diabetes Mellitus: Type 2 and Gestational
Dipeptidyl Peptidase 4 Inhibitors
Atherosclerosis III: Management
Type II Diabetes II: Pathophysiology

